CClinicalTrials.gg
Status unknownNCT03974256AUTOTECUpdated Aug 5, 2021

Preparation of Radiopharmaceuticals by Automaton: Operators Dosimetry

An interventional study of Training in the use of the automaton in Exposure, Radiation, sponsored by Central Hospital, Nancy, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The radiopharmaceuticals manipulation used in nuclear medicine department is a significant source of radiation for operators.

According to Article R. 4451-13 of the Labor Code, the exposure limit for hands and skin (average dose over a surface of 1 cm²) received during twelve consecutive months can't exceed the annual dose limit 500 millisieverts (mSv).

The radiopharmaceuticals manipulation exposes operators to the risk of exceeding this limit, as has been shown in a European study.

At present, there are automatons on the market but only for radiopharmaceutical fluorodeoxyglucose (FDG).

One of the advantages of such an automaton is to reduce irradiation of operators' hands during the radiopharmaceuticals preparation. This reduction can reach 95% according to certain authors and the type of automaton.

This study therefore proposes to evaluate the effect of an original, newly designed automaton on operators' dosimetry and the labelled radiopharmaceuticals' quality.

The hypothesis emitted in this study is that the use of this automaton would allow to reduce drastically operators' hands exposure and probably also to improve the precision of the prepared syringes.

This study will be done in a paired way, require a randomization in cross-over and each of the subjects included will be its own witness.

Read the detailed description

Currently, radiopharmaceuticals for diagnostic purposes are prepared by operators, Technologist in Medical Electro-Radiology or/and Pharmacy Technicians, manually for radiopharmaceuticals labelled with Technetium-99m (99mTc), or using an automaton for radiopharmaceuticals FDG.

At present, there are automatons on the market but only for radiopharmaceuticals FDG.

However, these automatons are currently only used to split into individual doses radiopharmaceuticals FDG, the labelling radiopharmaceuticals being carried out before delivery in nuclear medicine departments.

The Sysark SAS's company has created and patented, with the collaboration of the Center of Research in Automatic Control of Nancy (CRAN, mixed unite of research 7039 common to the University of Lorraine and the CNRS) an innovative automaton for the preparation of radiopharmaceuticals labelled with 99mTc, used to perform scintigraphy examinations of nuclear medicine department.

02

Conditions studied

  • Exposure, Radiation

Keywords

  • Automaton
  • Dosimetry
  • Radiopharmaceutical
  • Technetium-99m
03

In context

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult (age > 18 years)
  • Operators: Technologist in Electro-Radiology Medical / Pharmacy Technician
  • Operators experienced and autonomous in labelling radiopharmaceuticals with technetium-99m, at least one year
  • Operators having agreed to participate in the study, having received complete information on the organization of the research and having signed a free and informed consent
  • Operators affiliated to a social security scheme or beneficiary of such a scheme

Exclusion criteria

Exclusion Criteria:

  • A woman of childbearing age who doesn't have effective contraception
  • Persons referred in Articles L. 1121-5, L 1121-8 of the French Public Health Code:

    • Pregnant woman, parturient or mother who is breastfeeding
    • Chil (not emancipated)
    • Adult subject to a measure of legal protection (guardianship, curators, safeguard of justice)
    • Adult unable to express consent
  • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • No intervention
    Group standard method

    Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics

  • Experimental
    Group automated method

    Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics

    Other: Training in the use of the automaton

Interventions

  • OtherTraining in the use of the automaton

    2 days training on automaton use

06

What researchers measure

Primary outcomes

  1. Total radiopharmaceutical activity prepared in mega-becquerel (MBq)

    For each of the two methods of preparation

    Time frame: Throughout 4 working days of each methods

  2. Number of days of handling

    For each of the two methods of preparation

    Time frame: Throughout 4 working days of each methods

Secondary outcomes

  1. Accuracy in terms of activity (MBq) of prepared syringes, expressed as a percentage (%) of the prescribed target value, and compared between the automated device and the conventional manual method

    For each of the two methods of preparation

    Time frame: Throughout 4 working days of each methods

  2. A likert of 4 modalities will be used to evaluate the level of comfort in the automaton by operators (from "Very uncomfortable" to "Very comfortable")

    During the automated method of preparation

    Time frame: After 4 working days of this method

  3. A likert of 4 modalities will be used to evaluate the confidence level in the automaton by operators (from "Not at all confident" to "Totally confident")

    During the automated method of preparation

    Time frame: After 4 working days of each methods

  4. Level of operators' irradiation, measured by the breast dosimeter during the 4 days of preparation (in µSv) and expressed in relation to the total radiopharmaceuticals' activity prepared during the same period (in MBq)

    For each of the two methods of preparations

    Time frame: Throughout 4 working days of each methods

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03974256
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Jan 1, 2022 (estimated)
Primary completion
Jan 1, 2023 (estimated)
Completion
Jul 1, 2024 (estimated)
Last update
Aug 5, 2021

Study contacts

Rachel GRIGNON, Technologist
Contact
r.grignon@chru-nancy.fr
+33 383155423
Véronique ROCH, MSc
Contact
v.roch@chru-nancy.fr
+33 383154276
Rachel GRIGNON, Technologist
principal investigator · GIE NANCYCLOTEP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion